GED 0507-34-Levo

Drug Profile

GED 0507-34-Levo

Alternative Names: GED-0507; GED-0507-34; N-acety-GED-0507-34

Latest Information Update: 21 Feb 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Giuliani
  • Developer Nogra Pharma
  • Class Anti-inflammatories; Antiulcers
  • Mechanism of Action Peroxisome proliferator-activated receptor gamma modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Acne vulgaris
  • No development reported Ulcerative colitis

Most Recent Events

  • 02 Jul 2016 Phase-II clinical trials in Acne vulgaris in Hungary (Topical) (EudraCT2016-000540-33)
  • 20 Jun 2016 PPM Services plans the proof-of-concept phase II SEGMENT trial for Ulcerative colitis in Canada and USA (PO) (NCT02808390)
  • 13 Sep 2015 No recent reports of development identified - Phase-II for Ulcerative colitis in Italy (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top